Search results
Results from the WOW.Com Content Network
Retroperitoneal DDL is the most common, surgically unaccessible and serious form of DDL: it has a recurrence rate of 66% and a five-year overall survival rate of 54%. [31] The primary treatment option for retroperitoneal DDL is surgical resection.
Treatment for neurofibrosarcoma is similar to that of other cancers. Surgery is an option; the removal of the tumor along with surrounding tissue may be vital for the patient's survival. For discrete, localized tumors, surgery is often followed by radiation therapy of the excised area to reduce the chance of recurrence. For patients who have ...
Undifferentiated pleomorphic sarcoma (UPS), also termed pleomorphic myofibrosarcoma, [1] high-grade myofibroblastic sarcoma, and high-grade myofibrosarcoma, [2] is characterized by the World Health Organization (WHO) as a rare, poorly differentiated neoplasm (i.e., an abnormal growth of cells that have an unclear identity and/or cell of origin). [3]
The association of idiopathic retroperitoneal fibrosis with various immune-related conditions and response to immunosuppression led to a search for an autoimmune cause of idiopathic RPF. [ 5 ] [ 6 ] Many of these previously idiopathic cases can now be attributed to IgG4-related disease , an autoimmune disorder proposed in 2003.
Lighter Side. Medicare. News
Gallium scan showing panda (A) and lambda (B) patterns, considered specific for sarcoidosis in the absence of histological confirmation. In the past, the gallium scan was the gold standard for lymphoma staging, until it was replaced by positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG).
The retroperitoneal space (retroperitoneum) is the anatomical space (sometimes a potential space) behind (retro) the peritoneum. It has no specific delineating anatomical structures. It has no specific delineating anatomical structures.
Tumors may be misdiagnosed (30–40%) [25] due to their rarity and a lack of knowledge; patients may initially be given inappropriate treatment or poor prognoses due to misdiagnosis with conditions such as malignant sarcoma. [48] [49] Patients may need to visit multiple healthcare providers to receive a diagnosis, causing delay in care.